Abstract
Background Inflammation is currently recognized as one of the major causes of premature delivery. As a member of the IL-1β family, interleukin-33 (IL-33) has been shown to be involved in a variety of pregnancy-related diseases. This study aims to investigate the potential function of IL-33 in uterine smooth muscle cells during labor.
Methods Samples of myometrium from term pregnant (≥37 weeks gestation) women were frozen or cells were isolated and cultured. Immunohistochemistry and western blotting were used to identify the distribution of IL-33. Cultured cells were incubated with LPS to mimic inflammation as well as 4μ8C to block endoplasmic reticulum (ER) stress and BAPTA-AM, a calcium chelator.
Results Similar with onset of labor, LPS could reduce the expression of nuclear IL-33 in a time-limited manner and induced ER stress. Meanwhile, Knockdown of IL-33 increased LPS-induced calcium concentration, ER stress and phosphorylation of NF-κB and p38. In addition, siRNA IL-33 further simulates LPS enhanced COX-2 expression via NF-κB and p38 pathways. IL-33 expression was decreased in the nucleus with the onset of labor. LPS induced ER stress and increased expression of the labor-associated gene, COX-2, as well as IL-6 and IL-8 in cultured myometrial cells. IL-33 also increased COX-2 expression. However, after IL-33 was knockdown, the stimulating effect of LPS on calcium was enhanced. 4μ8C also inhibited the expression of COX-2 markedly. The expression of calcium channels on the membrane and intracellular free calcium ion were both increased accompanied by phosphorylated NF-κB and p38.
Conclusions These data suggest that IL-33 may be involved in initiation of labor by leading to stress of the ER via an influx of calcium ions in human uterine smooth muscle cells.
Funding This study was supported by grants from the National Natural Science Foundation of China (Nos. 81300507).
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by grants from the National Natural Science Foundation of China (Nos. 81300507).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee of the First Affiliated Hospital of Nanjing Medical University gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data generated or analyzed during this study are included in the manuscript and supporting files.